Treatment of idiopathic inflammatory myopathies.
نویسندگان
چکیده
PURPOSE OF REVIEW This article reviews the results of recent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests an approach to treating patients with inflammatory myopathy. RECENT FINDINGS We reviewed 10 double-blind, placebo-controlled therapeutic trials in patients with inflammatory myopathy. Only one, using intravenous immunoglobulin in refractory dermatomyositis, indicated benefit. A brief trial of azathioprine in polymyositis and eight studies using various treatments in inclusion body myositis did not show benefit. SUMMARY There have been no adequate double-blind, placebo-controlled therapeutic trials of dermatomyositis and polymyositis. It is generally accepted, however, that these disorders respond to immunosuppressive agents. Prednisone is usually the initial treatment. There is no agreement on how prednisone should be administered and even less agreement about other agents. Inclusion body myositis, which now appears to be the most common (in adults), is unresponsive to immunosuppressive and immunomodulating therapies. There are candidate treatments for inclusion body myositis and a need for additional double-blind, placebo-controlled therapeutic trials in all patients with inflammatory myopathy.
منابع مشابه
Approach to Diagnosis and Management of an Idiopathic Inflammatory Myopathy
Idiopathic inflammatory myopathies are a group of autoimmune diseases characterized by proximal muscle weakness and inflammation of skeletal muscle. Specific forms of idiopathic inflammatory myopathy include polymyositis, dermatomyositis, and inclusion body myositis. Inflammatory myopathies have a bimodal distribution, occurring in patients between 10 and 15 years and 45 and 60 years of age, ex...
متن کاملCurrent pharmacological treatment of idiopathic inflammatory myopathies.
The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype. There are few randomised, double blind placebo controlled ...
متن کاملOne year in review 2017: idiopathic inflammatory myopathies.
Every year new concepts about pathogenesis, serology, diagnosis and treatment in inflammatory myopathies (IIMs) have been provided. The purpose of this manuscript is to summarise the most relevant literature contributions published over the last year about these complex and rare diseases.
متن کاملDeciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.
The idiopathic inflammatory myopathies or myositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune diseases defined by chronic muscle weakness and inflammation of unknown etiology and result in significant morbidity and mortality. Research suggests that categorizing heterogeneous myositis syndromes into mutually exclusive ...
متن کاملIdiopathic infl ammatory myopathies : An update
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disease with complex clinical features. The histological features of them usually include various degrees of degenerative changes and inflammatory (usually lymphocytic) infiltrates [1]. Histopathological evaluation is one of the key tools for the diagnosis of IIM. Because of the complexity of clinical, morphological and labor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Current opinion in neurology
دوره 16 5 شماره
صفحات -
تاریخ انتشار 2003